1 / 3

Immuno-oncology Drugs Market - Forecast till 2025

Introduction of novel immune-oncology therapies with lesser side effects is driving growth of the global immune-oncology drugs market

RupeshD
Download Presentation

Immuno-oncology Drugs Market - Forecast till 2025

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immuno-oncology Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2018 - 2026 Immuno-oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy), by Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers), and by Region - Global Trends, and Forecast till 2025 Immuno-oncology involves use of patients’ immune system to fight against cancer. Immuno- oncology uses novel immunotherapies that boost the immune system of patients. These therapies target the immune system of the body instead of the tumors and enable the immune system to recognize and target cancer cells. Immuno-oncology does not affect the functioning of healthy cells as opposed to conventional therapies such as chemotherapy and radiation therapy. Long term response can be generated with the help of these therapies as they provide long- lasting memory to the immune system. Immune system adapts to the cancer over time and provides long term response to the cancer. Immuno-Oncology therapy work against a wide variety of cancer, which include non-small cell lung cancer, acute myeloid leukemia, lymphoma, multiple myeloma, breast cancer, and others. Immuno-oncology uses different types of cell-based immune therapies such as monoclonal antibodies, immune checkpoint inhibitors, cytokine based immunotherapy, cancer vaccines, and other therapies. Depending on the functioning of these therapies they are further classified into subtypes such as radiolabeled antibodies, chemo labeled antibodies, and bispecific monoclonal antibodies. Commercially available immune-oncology therapies include Iplimumab, Nivolumab, Rituximab, Blinatumomab, Proleukin, Gardasil, and Kymriah. Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1271 Cancer treatment has become more refined with improved treatment success rate due to improved therapeutic outcomes. This has been possible due to deepened understanding of the

  2. disease pathophysiology, functioning of the tumor cells, and effective ways to tackle with the same. Immuno-oncology therapies exhibit lesser side effects as compared to conventional cancer therapies such as chemotherapy, radiation therapy, and others. Immuno-oncology therapy directly target the immune system of the body and does not harm healthy cells in the process, whereas, conventional therapies such as targeted therapy, chemotherapy, and radiation therapy affect cancerous as well as healthy cells extensively. Novel immune therapies can restore the ability of the immune system to identify and eliminate cancer cells, which is generally suppressed during course of cancer progression. Manufactures are developing immuno-oncology based therapies, which are tailored to attack or block particular targets. For instance, Iplimumab, a, human monoclonal antibody, which blocks cytotoxic T- lymphocyte-associated antigen-4 is available. Furthermore, agents focusing on specific immune regulatory checkpoints programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD- L1) such as Nivolumab, Atezolimumab, and Pembrolizumab are being used for cell lung cancer. Monoclonal antibodies have been further developed into conjugated monoclonal antibodies, which are combined with other agents such as radiolabeled antibodies and chemo labeled antibodies. Cancer vaccines have also been developed such as Sipuleucel-T, Gardasil, and Cervarix. These vaccines either work as preventive vaccines or therapeutic vaccines. Adoptive cell transfer therapies is a new therapy emerging in the immuno-oncology such as CAR-T Cell Therapy under, which Kymriah and Yescarta are available. Browse More About the Keyword Market Study @ https://www.coherentmarketinsights.com/market-insight/immuno-oncology-drugs-market-1271 Report includes chapters which deeply display the following deliverable about industry: • Immuno-oncology Drugs Market Research Objective and Assumption • Immuno-oncology Drugs Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Immuno-oncology Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Immuno-oncology Drugs Market, By Regions • Immuno-oncology Drugs Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Immuno-oncology Drugs Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Immuno-oncology Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List.

  3. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Immuno-oncology Drugs Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Table of Contents of Keyword Market Report: 1. Research Objective and assumption 2. Market Purview 3. Market Dynamics, Regulations, and Trends Analysis 4. Keyword Market, By Advanced Water Meters, 2017 - 2025 (USD Million) 5. Keyword Market, By Service, 2017 - 2025 (USD Million) 6. Keyword Market, By Solution, 2017 - 2025 (USD Million) 7. Keyword Market, By Regions, 2017 - 2025 (USD Million) 8. Competitive Landscape Ask for Discount before Buying @ https://www.coherentmarketinsights.com/insight/request-discount/1271 About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

More Related